Two medicines, side by side
Dexlansoprazole vs lansoprazole
Dexlansoprazole and lansoprazole are both labeled for acid reflux and ulcers. Drugs@FDA records approvals of dexlansoprazole since 2009 and of lansoprazole since 1995. Pharmacies paid $3.71 per dexlansoprazole DR 60 mg capsule and $0.106 per lansoprazole DR 30 mg capsule (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like.
Check it at the source: the dexlansoprazole FDA label on DailyMed (effective February 17, 2025); the lansoprazole FDA label on DailyMed (effective June 24, 2025).
Highlights of the dexlansoprazole record
Dexlansoprazole (Dexilant) · label of February 17, 2025
Used for
From the label: indicationsDEXILANT is a proton pump inhibitor (PPI) indicated in patients 12 years of age and older for: Healing of all grades of erosive esophagitis (EE). ( 1.1 ) Maintenance of healed EE and relief of heartburn. ( 1.2 ) Treatment of symptomatic non-erosive gastroesophageal reflux disease (GERD). […]
On the market
- Earliest approval on file
- January 30, 2009
- Generic labelers
- 9 labelers
- Pharmacy cost
- $3.71 per capsule
Supply and safety
- Shortage
- No current entry
- Recalls
- 0
Highlights of the lansoprazole record
Lansoprazole (Prevacid) · label of June 24, 2025
Used for
From the label: indications• treats frequent heartburn (occurs 2 or more days a week) • not intended for immediate relief of heartburn; this drug may take 1 to 4 days for full effect
On the market
- Earliest approval on file
- May 10, 1995
- Generic labelers
- 59 labelers
- Pharmacy cost
- $0.106 per capsule
Supply and safety
- Shortage
- No current entry
- Recalls
- 15
Source: FDA drug labels via openFDA (Dexlansoprazole label of February 17, 2025, Lansoprazole label of June 24, 2025); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do dexlansoprazole and lansoprazole differ on the record?
Both are in FDA's class proton pump inhibitors.
Generics: dexlansoprazole since 2017; lansoprazole since 2009 (Drugs@FDA).
| Dexlansoprazole | Lansoprazole | |
|---|---|---|
| Labeled for | Acid reflux and ulcers | Acid reflux and ulcers |
| Pharmacologic class | Proton Pump Inhibitor | Proton Pump Inhibitor |
| How it works (label) | Dexlansoprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the (H + , K + )-ATPase at the secretory surface of the gastric parietal cell. | n/a |
| Half-life (label) | NT Once Daily for 7 Days Dose C max (ng/mL) AUC tau (ng∙h/mL) CL/F (L/h) 30 mg (N=17) 691 (53) 2,886 (47) 12.8 (48) 60 mg (N=18) 1,136 (51) 5,120 (58) 15.3 (49) Age: Geriatric Population The terminal elimination … | n/a |
| Earliest approval on file (Drugs@FDA) | January 30, 2009 | May 10, 1995 |
| First generic approved | April 19, 2017 | November 10, 2009 |
| Generic labelers (NDC) | 9 labelers | 59 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $3.71 per capsule (Dexlansoprazole DR 60 mg capsule) | $0.106 per capsule (Lansoprazole DR 30 mg capsule) |
| 12-month price change | -18% | +0.7% |
| Boxed warning | No | No |
| Shortage now | No current entry | No current entry |
| Recalls recorded | 0 | 15 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 41,466 | 177,061 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
Do their labels mention each other?
Dexlansoprazole label, warnings and precautionsNonclinical studies in juvenile rats with lansoprazole have demonstrated an adverse effect of heart valve thickening.
Source: FDA drug labels via openFDA
What next?
- Alternatives to dexlansoprazole
- every medicine labeled for the same conditions